Lupus (SLE) trials in Italy

In Italy 26 Also abroad 354

26 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Where
Ancona, Caserta, Ferrara, Milan, Naples, Padova, Pisa, Rome, Turin
Age
12 years to 100 years
People
550 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06133972 · EU 2023-505929-14-00
Phase 1Taking people
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Where
Brescia, Rome, Rozzano
Age
18 years to 75 years
People
46 worldwide
Run by
Genentech, Inc.
See details and how to joinNCT07629583 · EU 2025-522904-26-00
Phase 3Taking people
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
Where
Florence, Genoa, Milan, Rome, Rozzano
Age
18 years to 75 years
People
202 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07332481 · EU 2025-523871-44-00
Phase 3Taking people
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
Where
Catania, Modena, Rome, Verona
Age
18 years to 75 years
People
202 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07355218 · EU 2025-524855-30-00
Phase 2Taking people
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Where
Genoa, Milan, Rome
Age
5 years to 17 years
People
40 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05039619 · EU 2023-505825-15-00
Phase 3Taking people
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Where
Ancona, Catania, Milan, Perugia, Rome, Rozzano, Turin, Udine, Verona
Age
18 years to 75 years
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07438496 · EU 2025-523552-31-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Where
Brescia, Genoa, Milan, Modena, Monza, Padova, Pisa, Rome, Rozzano, Udine
Age
16 years and over
People
450 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT06617325 · EU 2023-508191-11-00
No phaseTaking people
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
Where
Brescia, Ferrara, Padova, Torino
Age
16 years and over
People
223 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07175285
Phase 1Taking people
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
Where
Rome, Rozzano
Age
18 years to 75 years
People
21 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07363590 · EU 2025-523412-36-00
Phase 3Taking people
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Where
Brescia, Catania, Cona, Florence, Milan, Pavia, Roma
Age
5 years to 80 years
People
1,072 worldwide
Run by
AstraZeneca
See details and how to joinNCT07691970
Phase 3Not yet taking people in Italy
Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Beneﬁted from Continued Treatment.
Where
Brescia, Ferrara, Florence, Milan, Rome
People
340 worldwide
Run by
AstraZeneca AB
See details and how to join2026-526419-13-00 · EU 2026-526419-13-00
Phase 2Taking people
A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Where
Brescia, Rome, Rozzano, Turin
Age
18 years and over
People
30 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07598396 · EU 2024-519930-22-00
Phase 3Enrolling by invitation
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
Where
Brescia, Catania, Ferrara, Genoa, Milan, Modena, Monza, Padova, Pisa, Rome, Rozzano, Udine
Age
16 years and over
People
760 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT04976322 · EU 2023-506368-14-00
Phase 1Not yet taking people in Italy
A study to learn how dapirolizumab pegol transfers to babies from pregnant mothers with active systemic lupus erythematosus
Where
DO NOT EDIT
Age
Up to 64 years
People
10 worldwide
Run by
UCB Biopharma
See details and how to join2025-524595-37-00 · EU 2025-524595-37-00
Phase 3Enrolling by invitation
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
Where
Rome
Age
18 years and over
People
864 worldwide
Run by
Biogen
See details and how to joinNCT05352919 · EU 2023-505635-13-00
Phase 2Taking people
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Where
Milan, Rozzano, Turin
Age
18 years to 75 years
People
220 worldwide
Run by
Amgen
See details and how to joinNCT06570798
Phase 3Taking people
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
Where
Brescia, Catania, Ferrara, Florence, Milan, Padova, Pisa, Rome, Rozzano, Udine
Age
18 years and over
People
113 worldwide
Run by
AstraZeneca AB
See details and how to join2025-523670-17-00 · EU 2025-523670-17-00
Phase 3Taking people
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Where
Florence, Genoa, Milan, Padova, Rome
Age
5 years to 17 years
People
100 worldwide
Run by
AstraZeneca
See details and how to joinNCT05835310 · EU 2022-502289-25-00
Phase 1Not yet taking people in Italy
Basket trial for B-cEll driven severe auToimmunE and aLoimmune diseases (chronic Graft vErsUs host diseaSe) treated with anti-CD19 CAR T-cell thErapy
Where
Bologna, Rome
People
24
Run by
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
See details and how to join2025-522821-37-00 · EU 2025-522821-37-00
Phase 3Taking people
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
Where
Brescia, Catania, Ferrara, Florence, Milan, Padova, Pisa, Roma, Rozzano, Udine
Age
18 years to 70 years
People
245 worldwide
Run by
AstraZeneca
See details and how to joinNCT07430306
Phase 3Taking people
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1)
Where
Pisa, Verona
Age
18 years and over
People
147 worldwide
Run by
Bristol-Myers Squibb Services Unlimited Company
See details and how to join2022-500699-76-00 · EU 2022-500699-76-00
No phaseTaking people
Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.
Where
Ancona, Bari, Brescia, Cona, Florence, Milan, Modena, Monserrato, Naples, Padova, Palermo, Pavia, Pisa, Roma, Rozzano, San Giovanni Rotondo, Torino, Trieste, Udine, Verona
People
218
Run by
AstraZeneca
See details and how to joinNCT07330245
No phaseTaking people
Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
Where
Rozzano
Age
18 years and over
People
300 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06527872
Phase 1Taking people
A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
Where
Ferrara, Rozzano
Age
18 years to 70 years
People
44 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07371468 · EU 2025-522932-15-00
Phase 4Taking people
Steroid withdrawal in SLE
Where
Brescia, Cagliari, Ferrara, Milan, Pisa
Age
18 years and over
People
252
Run by
Azienda Ospedaliero Universitaria Pisana
See details and how to join2024-518580-35-00 · EU 2024-518580-35-00